CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+5.7%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(-5.5%)
Cap. Flow
-$636M
Cap. Flow
% of AUM
-55.6%
Top 10 Holdings %
Top 10 Hldgs %
63.1%
Holding
45
New
5
Increased
7
Reduced
10
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$31.2M |
| 2 |
Structure Therapeutics
GPCR
|
$13.3M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$4.5M |
| 4 |
Sana Biotechnology
SANA
|
$4.47M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$4.23M |
Top Sells
| 1 |
GeneDx Holdings
WGS
|
$590M |
| 2 |
Illumina
ILMN
|
$22.5M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$17.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$16.6M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$16.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioLife Solutions
BLFS
$1.2B
| $171M | 14.91% | 7,721,535 +150,000 | +2% | +$3.32M |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $116M | 10.16% | 1,015,000 -145,000 | -13% | -$16.6M |
|
3
Relay Therapeutics
RLAY
$619M
| $75.3M | 6.58% | 5,998,574 +300,000 | +5% | +$3.77M |
|
|
EQRX
4
DELISTED
EQRx, Inc. Common Stock
EQRX
| $73.5M | 6.43% | 39,527,669 | – | – |
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $53.2M | 4.65% | 280,000 +10,000 | +4% | +$1.9M |
|
6
Intellia Therapeutics
NTLA
$1.22B
| $52M | 4.54% | 1,275,000 | – | – |
|
7
Revolution Medicines
RVMD
$7.1B
| $48.4M | 4.23% | 1,810,000 | – | – |
|
8
Exact Sciences
EXAS
$8.98B
| $47M | 4.1% | 500,000 -65,000 | -12% | -$6.1M |
|
|
VERV
9
DELISTED
Verve Therapeutics
VERV
| $44.3M | 3.87% | 2,360,571 +240,000 | +11% | +$4.5M |
|
|
10
Structure Therapeutics
GPCR
$1.11B
| $41.4M | 3.62% | 997,017 +320,000 | +47% | +$13.3M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $39.2M | 3.42% | 620,000 -50,000 | -7% | -$3.16M |
|
12
Denali Therapeutics
DNLI
$2.23B
| $38.4M | 3.35% | 1,300,000 | – | – |
|
13
Tenaya Therapeutics
TNYA
$184M
| $37.5M | 3.27% | 6,381,377 +302,517 | +5% | +$1.78M |
|
|
CTLT
14
DELISTED
CATALENT, INC.
CTLT
| $31.2M | 2.73% | +720,000 | New | +$31.2M |
|
15
Pliant Therapeutics
PLRX
$101M
| $30.8M | 2.69% | 1,700,000 +25,000 | +1% | +$453K |
|
|
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $29.1M | 2.54% | 12,604,275 | – | – |
|
|
17
Illumina
ILMN
$15.8B
| $29.1M | 2.54% | 155,000 -120,000 | -44% | -$22.5M |
|
18
MaxCyte
MXCT
$148M
| $21.6M | 1.89% | 4,715,000 -210,000 | -4% | -$964K |
|
|
TSVT
19
DELISTED
2seventy bio
TSVT
| $20.5M | 1.79% | 2,023,913 | – | – |
|
20
4D Molecular Therapeutics
FDMT
$288M
| $19.3M | 1.69% | 1,070,000 | – | – |
|
|
21
GeneDx Holdings
WGS
$3.72B
| $18.4M | 1.61% | 3,095,511 -99,056,274 | -97% | -$590M |
|
22
Beam Therapeutics
BEAM
$1.66B
| $18.2M | 1.59% | 570,000 | – | – |
|
23
AbCellera Biologics
ABCL
$1.25B
| $16.3M | 1.42% | 2,520,000 | – | – |
|
24
Century Therapeutics
IPSC
$42.5M
| $10.1M | 0.89% | 3,206,380 | – | – |
|
25
Fate Therapeutics
FATE
$120M
| $9.76M | 0.85% | 2,050,000 | – | – |
|